Summary & Overview
HCPCS Q5126: Bevacizumab-maly (Alymsys) 10 mg Injection
HCPCS Level II code Q5126 designates a 10 mg unit of bevacizumab-maly (Alymsys), a biosimilar to bevacizumab used in oncology and certain ophthalmology indications. This drug-specific code matters nationally because biosimilars are increasingly used to expand access to biologic therapies and can influence drug spending, site-of-care decisions, and billing workflows across payers.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical role, typical sites of service for administration, and the payer landscape relevant to coverage and claims processing. The publication outlines expected benchmarks and reimbursement themes, common billing modifiers and their relevance to claims processing, and considerations for integrating Q5126 into service lines that manage biologic infusions.
The content provides practical context for clinicians, billing staff, and revenue cycle analysts: what the code represents, where the drug is commonly administered, and which major payers' policies typically drive coverage and reimbursement patterns. Data gaps from the input are noted where applicable.
Billing Code Overview
HCPCS Level II code Q5126 describes an injection of bevacizumab-maly, a biosimilar marketed as Alymsys, in a unit of 10 mg. The code represents the drug product formulation for administration of this bevacizumab biosimilar.
Service type: Drug administration (intravenous biologic infusion/injection)
Typical site of service: Hospital outpatient department, physician office infusion suite, or ambulatory infusion center
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical scenario involves an adult patient receiving an intravitreal or periocular medication administration of the bevacizumab biosimilar Q5126 (bevacizumab-maly, brand name Alymsys) supplied in a 10 mg vial for ophthalmic indications. Common clinical workflow: the patient presents to an ophthalmology clinic or ambulatory infusion center with decreased visual acuity or progressive retinal disease. After evaluation, including visual acuity, intraocular pressure check, and retinal imaging (optical coherence tomography), the ophthalmologist determines anti-VEGF therapy is indicated for conditions such as neovascular (wet) age-related macular degeneration, diabetic macular edema, or retinal vein occlusion. The medication is prepared in a sterile compounding area or pharmacy; the dose is drawn and labeled. The patient receives topical anesthesia and antisepsis; the clinician administers an intravitreal injection in the office procedure room. Post-procedure, the patient is observed briefly for adverse events and given post-injection instructions. Billing uses HCPCS Level II code Q5126 to report the biosimilar bevacizumab product; appropriate modifiers are appended as clinically applicable (e.g., for discarded drug amount or product provided by patient). Typical site of service: ophthalmology office or ambulatory infusion/clinic setting. Typical patient: adult with retinal vascular neovascularization or macular edema requiring anti-VEGF therapy, frequently older adults with comorbid diabetes or age-related degenerative disease.
Coding Specifications
| Modifier | Description | When to Use |
|---|